Brian B Hart1, Anna D Nordell2, Jason F Okulicz3,4, Adrian Palfreeman5, Andrzej Horban6, Eynat Kedem7, Jacqueline Neuhaus1, David R Jacobs8, Daniel A Duprez9, James D Neaton1. 1. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN. 2. North American Science Associates, Minneapolis, MN. 3. Infectious Disease Service, San Antonio Military Medical Center, Fort Sam Houston, TX. 4. Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD. 5. Department of Infectious Diseases, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom. 6. Department of Adult Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. 7. Department of Immunology, Allergy and AIDS, Rambam Health Care Center, Haifa, Israel. 8. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN. 9. Cardiovascular Division, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: To determine the rate of grade 4, potentially life-threatening events not attributable to AIDS, cardiovascular disease (CVD), or non-AIDS cancer among participants on antiretroviral therapy and to describe associations of these events with interleukin-6 (IL-6) and D-dimer. DESIGN: Cohort study. METHODS: HIV-infected participants on antiretroviral therapy (N = 3568) with an HIV-RNA level ≤ 500 copies/mL were followed for grade 4, AIDS, CVD, non-AIDS cancer, and all-cause mortality events. Grade 4 events were further classified masked to biomarker levels as reflecting chronic inflammation-related disease (ChrIRD) or not (non-ChrIRD). Associations of baseline IL-6 and D-dimer with events were studied using Cox models. RESULTS: Over a median follow-up of 4.3 years, 339 participants developed a grade 4 event (22.9 per 1000 person-years); 165 participants developed a ChrIRD grade 4 event (10.7 per 1000 person-years). Grade 4 events were more common than AIDS (54 participants), CVD (132), and non-AIDS cancer (80) events, any of which developed in 252 participants (17.1 per 1000 person-years). Grade 4 and AIDS events were associated with similar risks of death. Higher IL-6 [hazard ratio (HR) = 1.19 per doubling of biomarker; P = 0.003] and D-dimer (HR = 1.23; P < 0.001) levels were associated with an increased risk of grade 4 events. IL-6 associations were stronger for ChrIRD (HR = 1.38; P < 0.001) than non-ChrIRD grade 4 events (HR = 1.11; P = 0.21). CONCLUSIONS: Morbidity and mortality associated with activation of inflammatory and coagulation pathways include conditions other than AIDS, CVD, and non-AIDS cancer events. Effective inflammation-dampening interventions could greatly affect the health of people with HIV.
OBJECTIVE: To determine the rate of grade 4, potentially life-threatening events not attributable to AIDS, cardiovascular disease (CVD), or non-AIDS cancer among participants on antiretroviral therapy and to describe associations of these events with interleukin-6 (IL-6) and D-dimer. DESIGN: Cohort study. METHODS:HIV-infectedparticipants on antiretroviral therapy (N = 3568) with an HIV-RNA level ≤ 500 copies/mL were followed for grade 4, AIDS, CVD, non-AIDS cancer, and all-cause mortality events. Grade 4 events were further classified masked to biomarker levels as reflecting chronic inflammation-related disease (ChrIRD) or not (non-ChrIRD). Associations of baseline IL-6 and D-dimer with events were studied using Cox models. RESULTS: Over a median follow-up of 4.3 years, 339 participants developed a grade 4 event (22.9 per 1000 person-years); 165 participants developed a ChrIRD grade 4 event (10.7 per 1000 person-years). Grade 4 events were more common than AIDS (54 participants), CVD (132), and non-AIDS cancer (80) events, any of which developed in 252 participants (17.1 per 1000 person-years). Grade 4 and AIDS events were associated with similar risks of death. Higher IL-6 [hazard ratio (HR) = 1.19 per doubling of biomarker; P = 0.003] and D-dimer (HR = 1.23; P < 0.001) levels were associated with an increased risk of grade 4 events. IL-6 associations were stronger for ChrIRD (HR = 1.38; P < 0.001) than non-ChrIRD grade 4 events (HR = 1.11; P = 0.21). CONCLUSIONS: Morbidity and mortality associated with activation of inflammatory and coagulation pathways include conditions other than AIDS, CVD, and non-AIDS cancer events. Effective inflammation-dampening interventions could greatly affect the health of people with HIV.
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: Daniel A Duprez; James Otvos; Otto A Sanchez; Rachel H Mackey; Russell Tracy; David R Jacobs Journal: Clin Chem Date: 2016-05-12 Impact factor: 8.327
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton Journal: PLoS One Date: 2012-09-10 Impact factor: 3.240
Authors: John Danesh; Stephen Kaptoge; Andrea G Mann; Nadeem Sarwar; Angela Wood; Sara B Angleman; Frances Wensley; Julian P T Higgins; Lucy Lennon; Gudny Eiriksdottir; Ann Rumley; Peter H Whincup; Gordon D O Lowe; Vilmundur Gudnason Journal: PLoS Med Date: 2008-04-08 Impact factor: 11.069
Authors: Patrick H Maduna; Matt Dolan; Lwando Kondlo; Honey Mabuza; Judith N Dlamini; Mike Polis; Thabo Mnisi; Susan Orsega; Patrick Maja; Lotty Ledwaba; Thuthukile Molefe; Phumelele Sangweni; Lisette Malan; Gugu Matchaba; Paul Khabo; Greg Grandits; James D Neaton Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Birgit Grund; Jason V Baker; Steven G Deeks; Julian Wolfson; Deborah Wentworth; Alessandro Cozzi-Lepri; Calvin J Cohen; Andrew Phillips; Jens D Lundgren; James D Neaton Journal: PLoS One Date: 2016-05-12 Impact factor: 3.240
Authors: Alvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Jason V Baker; Michael J Vjecha; Marcelo H Losso; Hartwig Klinker; Gustavo Lopardo; Ian Williams; Jens D Lundgren Journal: PLoS One Date: 2014-03-13 Impact factor: 3.240
Authors: Anna D Nordell; Matthew McKenna; Álvaro H Borges; Daniel Duprez; Jacqueline Neuhaus; James D Neaton Journal: J Am Heart Assoc Date: 2014-05-28 Impact factor: 5.501
Authors: Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2020-09-23 Impact factor: 2.205
Authors: Mynor J Mendez Valdez; Victor M Lu; Enoch Kim; Sarah R Rivas; Vaidya Govindarajan; Michael Ivan; Ricardo Komotar; Avindra Nath; John D Heiss; Ashish H Shah Journal: J Neurooncol Date: 2022-07-20 Impact factor: 4.506
Authors: Christina Ekenberg; Joanne Reekie; Adrian G Zucco; Daniel D Murray; Shweta Sharma; Cameron R Macpherson; Abdel Babiker; Virginia Kan; H Clifford Lane; James D Neaton; Jens D Lundgren Journal: AIDS Date: 2021-04-01 Impact factor: 4.632
Authors: Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga Journal: J Assoc Nurses AIDS Care Date: 2021 May-Jun 01 Impact factor: 1.809
Authors: Thomas A Premeaux; Shireen Javandel; Kalei R J Hosaka; Meredith Greene; Nicholas Therrien; Isabel E Allen; Michael J Corley; Victor G Valcour; Lishomwa C Ndhlovu Journal: Front Immunol Date: 2020-06-30 Impact factor: 7.561